Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Exenatide regulatory status

Current status of Exenatide in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of Exenatide?

Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 30, 2026
FDA and compounding
FDA approved for type 2 diabetes (Byetta April 2005, Bydureon January 2012, Bydureon BCise October 2017). On August 16, 2024 the manufacturer notified FDA that it would permanently discontinue marketing Byetta and Bydureon BCise. FDA approved a generic exenatide injection that references Byetta on November 19, 2024 (ANDA 206697), and Drugs@FDA lists it as a prescription product. Because exenatide is a component of approved drugs, 503A pharmacies may compound it only for a documented patient specific need and may not produce essentially a copy of a marketed product. Exenatide was not part of the semaglutide and tirzepatide shortage era.
WADA
Not WADA prohibited
Access path
  1. Prescription from a licensed provider (in person or telehealth). The manufacturer has moved to discontinue the brand products Byetta and Bydureon BCise, and FDA has approved a generic exenatide injection that references Byetta.
  2. Not available through compounding pharmacies or telehealth peptide clinics as a compounded product.
  3. Products labeled research use only are unapproved drugs when sold for human use.

Full Exenatide page: evidence, dosing in the literature, and sources

How has the status of Exenatide changed over time?

  1. FDA

    FDA approves Bydureon, once-weekly extended-release exenatide

    FDA approved the extended-release, once-weekly formulation of exenatide (Bydureon) for type 2 diabetes after earlier complete response letters.

  2. FDA

    FDA approves Byetta (exenatide), the first GLP-1 receptor agonist

    FDA approved twice-daily exenatide injection (Byetta) as adjunctive therapy for type 2 diabetes, the first GLP-1 receptor agonist to reach the US market.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Exenatide and the source of each dated event.

  1. [1]FDA prescribing information for Byetta (exenatide) injection, via DailyMedFDA, 2025
  2. [2]FDA prescribing information for Bydureon BCise (exenatide extended-release) injectable suspension, via DailyMedFDA, 2025
  3. [3]WADA Prohibited ListWADA, 2026
  4. [4]WADA 2027 Prohibited List (published September 21, 2026, in force January 1, 2027)WADA, 2026
  5. [5]FDA: Exenatide pediatric postmarketing pharmacovigilance review (records the August 16, 2024 notifications to permanently discontinue Byetta and Bydureon BCise)FDA
  6. [6]Drugs@FDA: ANDA 206697, exenatide injection referencing Byetta (approved November 19, 2024)FDA, 2024
  7. [7]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  8. [8]Drugs@FDA: Bydureon (exenatide extended-release) NDA 022200FDA, 2012
  9. [9]Drugs@FDA: Byetta (exenatide) NDA 021773FDA, 2005